Login to Your Account

Arrow Out-Licenses RSV Drug To Novartis For Up To $227M

By Nuala Moran

Thursday, July 7, 2005
LONDON - Arrow Therapeutics Ltd. landed its first deal, licensing A-60444, a small-molecule inhibitor of respiratory syncytial virus, to Novartis Pharma AG for a $10 million down payment and $217 million linked to development milestones, followed by royalties. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription